目的：观察胰激肽原酶治疗糖尿病早期视网膜病变的临床效果。 方法：将230例395眼糖尿病视网膜病变（Ⅰ～Ⅲ期）患者随机分成两组，治疗组120例210眼在常规治疗基础上加用胰激肽原酶治疗12mo，对照组110例185眼给予常规治疗12mo。观察治疗前后眼底、血管造影（FFA）、视力的改变。 结果：治疗组眼底改善较对照组明显升高，视力有所提高（P＜0.05）。 结论：胰激肽原酶治疗糖尿病早期视网膜病变效果明显，对糖尿病早期视网膜病变患者治疗有积极意义。

AIM:To observe the clinical effects of pancreatic kininogenase for treatment of early diabetic retinopathy(DR). METHODS:Totally 230 cases (395 eyes) of DR (Ⅰ-Ⅲ period) patients were randomly divided into two groups. On the basis of conventional therapy, the treatment group of 120 cases (210 eyes) were treated with pancreatic kininogenase for 12 months. The control group of 110 cases (185 eyes) received conventional therapy for 12 months. The changes in fundus, fluorescence fundus angiography (FFA) and vision were observed before and after treatment. RESULTS:The fundus improvement in treatment group was significantly higher than that in control group, the visual acuity improved (P<0.05). CONCLUSION: Pancreatic kininogenase for treatment of early DR is effective, which has positive significance for early DR patients.